Clinical Trials

Lung Cancer Trials

Learn More About Our Lung Cancer Trials

  • 1 EMR 100070-004 Show More

    EMR 100070-004 – A Phase III open-label, multicenter trial of MSB0010718C versus Docetaxel in subjects with non-small cell lung cancer that has progressed after a platinum-containing doublet.

    1. WHAT TYPE OF CANCER? WHAT STAGE?
    2nd line lung has opened.

    2. WHO IS ELIGIBLE?

    3. HOW WILL I BE TREATED?
    MSB0010718C- PDL1- Avelumab.

    For Physicians: More information about this specific trial at clinicaltrials.gov

  • 2 SWOG 1400 Show More

    SWOG 1400 – Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer.

    1. WHAT TYPE OF CANCER? WHAT STAGE?
    Lung Cancer

    2. WHO IS ELIGIBLE?
    Patients who need Second Line Therapy of Squamous Cell Lung Cancer.

    3. HOW WILL I BE TREATED?
    Patients will have therapies directed by tumor genetics.

    For Physicians: More information about this specific trial at clinicaltrials.gov

  • 3 E4512 Show More

    E4512 – A Phase III Double-Blinded Trial for Surgically Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein.

    1. WHAT TYPE OF CANCER? WHAT STAGE?
    Lung cancer, Surgically Removed

    2. WHO IS ELIGIBLE?
    Patinets who have an ALK mutation.

    3. HOW WILL I BE TREATED?
    Patients may get Crizonitib (a drug approved for ALK+ lung cancer).

    For Physicians: More information about this specific trial at clinicaltrials.gov

  • 4 A081105 Show More

    A081105 – Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small.

    1. WHAT TYPE OF CANCER? WHAT STAGE?
    Lung Cancer

    2. WHO IS ELIGIBLE?
    EGFR Mutant Non-small Cell Lung Cancer

    3. HOW WILL I BE TREATED?
    Erlotinib (antibody-based biologic)

    For Physicians: More information about this specific trial at clinicaltrials.gov

  • 5 A151216 Show More

    A151216 – Genetic Testing For Patients with Resectable or Resected Lung Cancer: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST).

    1. WHAT TYPE OF CANCER? WHAT STAGE?
    Lung Cancer

    2. WHO IS ELIGIBLE?
    Patients whose disease is resected (surgically removed).

    3. HOW WILL I BE TREATED?
    Genetic Testing will be incorporated to learn more about tumor biology.

    For Physicians: More information about this specific trial at clinicaltrials.gov

EJGH Trials Send an Inquiry

Click here